ContraBand
Phase 1- Indications
- Heart failure with reduced ejection fraction, Pulmonary hypertension, Right heart failure
Company intelligence / Profile preview
Restore Medical has developed ContraBand™, the world’s first transcatheter pulmonary artery banding system for HFrEF patients. The device is minimally invasive and targets symptomatic HFrEF patients who remain symptomatic despite guideline-directed medical therapy. Early feasibility studies have shown significant improvements in left ventricular volume reduction, hemodynamic function, and physical capacity. The FDA granted Breakthrough Device Designation based on these promising safety and efficacy results from ongoing trials.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Restore Medical.